People sometimes ask whether they can move from Suboxone or another buprenorphine treatment directly onto naltrexone. The short answer is that the transition is possible for selected patients, but it is not a simple same-day medication switch.

Buprenorphine is an opioid receptor partial agonist. Naltrexone is an opioid antagonist. That difference matters because naltrexone can displace remaining opioid activity and precipitate an abrupt withdrawal syndrome if physical opioid dependence is still present.

Why is the Suboxone-to-naltrexone transition different from changing ordinary medications?

Suboxone contains buprenorphine and naloxone. Buprenorphine binds strongly to the mu-opioid receptor and can suppress withdrawal and craving. Naltrexone works in the opposite direction: it blocks opioid receptors.

That means the body generally needs time to move out of physical opioid dependence before full antagonist treatment begins. FDA prescribing information for extended-release naltrexone warns that people transitioning from buprenorphine may remain vulnerable to precipitated withdrawal for as long as about two weeks. The exact timing varies and should be determined clinically rather than by a calendar alone.

Why can precipitated withdrawal happen?

If naltrexone is given while clinically meaningful opioid dependence remains, it can rapidly block opioid receptors and trigger a withdrawal syndrome that may be much more sudden than ordinary spontaneous withdrawal. Severe cases can require hospital-level treatment.

This is why a medically managed transition may include assessment of withdrawal symptoms, toxicology, observation, supportive medications and, in some settings, a naloxone challenge before antagonist treatment is given.

Does everyone need to stop buprenorphine for the same number of days?

No. Guidance often gives ranges rather than a single universal number. The FDA label for extended-release naltrexone recommends an opioid-free interval before treatment and specifically notes that patients coming from buprenorphine may remain vulnerable to precipitated withdrawal for up to about two weeks.

ASAM guidance has likewise advised allowing approximately 7–14 days between the last buprenorphine dose and naltrexone in conventional transitions. But clinical decisions also depend on the prior buprenorphine dose, duration of treatment, withdrawal symptoms, other opioid exposure and the individual patient’s physiology.

Can the transition be medically managed instead of simply waiting at home?

Yes. Research has examined structured approaches rather than asking patients to tolerate an unsupported opioid-free period.

In a randomized clinical trial of 101 clinically stable patients who wanted to discontinue buprenorphine and move to extended-release naltrexone, participants completed a brief buprenorphine taper with ancillary medications and counselling. Roughly seven in ten were successfully inducted onto extended-release naltrexone. Withdrawal after induction was generally mild in those who completed the protocol.

Another outpatient study evaluated a seven-day buprenorphine-naltrexone transition with ancillary medications. Most participants who completed the process showed improving withdrawal symptoms during the week, illustrating that medically supervised induction can be structured rather than left entirely to willpower.

Does adding very-low-dose naltrexone automatically make the transition easier?

Not necessarily. Research has tested ascending low doses of oral naltrexone during buprenorphine tapering, but randomized studies have not consistently shown higher induction success simply from adding low-dose naltrexone. The broader lesson is that the entire transition protocol matters: taper design, symptom control, clinical monitoring, patient motivation and timing.

Why do some people want to move from buprenorphine to naltrexone?

Buprenorphine is an evidence-based treatment for opioid use disorder and can be lifesaving. There is no need for a patient who is doing well on buprenorphine to stop simply because another medication exists.

However, some patients specifically want an antagonist-based pathway because they do not want ongoing opioid agonist activity, have experienced unwanted effects, have personal treatment goals that favor naltrexone, or prefer long-acting relapse-prevention treatment after physical dependence has resolved. That is a preference-and-suitability discussion, not a declaration that one medication is universally superior.

What happens during the opioid-free interval?

This is often the part patients fear most. Withdrawal symptoms can include anxiety, restlessness, gastrointestinal upset, muscle aches, insomnia, sweating and strong craving. Those symptoms can also increase the risk of abandoning the transition and returning to opioid use.

That is why a medically managed pathway may use non-opioid supportive medications, close monitoring, hydration, sleep support and psychological support rather than treating the waiting period as something the patient simply has to endure alone.

Why is relapse risk important during the transition?

When opioid tolerance falls, a return to the previous opioid dose can increase overdose risk. Any transition off agonist treatment therefore needs a relapse and overdose plan, not just a detox plan.

The clinical goal is not simply to remove buprenorphine. It is to move safely from one treatment state to another while reducing the period in which the patient is physically uncomfortable, unprotected by medication and vulnerable to return to use.

How does this connect to the broader naltrexone-induction problem?

The Suboxone-to-naltrexone question is one version of a larger clinical barrier: naltrexone is attractive to some people precisely because it is an antagonist, but becoming physiologically ready for an antagonist can be the difficult part.

For a broader explanation of how medically managed opioid-to-naltrexone transitions are approached, read Starting Recovery From Opioid Addiction Without Getting Clean First — How the Naltrexone Transition Works.

What happens after naltrexone starts?

Naltrexone can block opioid effects and support relapse prevention, but it does not rebuild a patient’s life by itself. Counselling, trigger management, family support, mental-health treatment and long-term recovery planning remain important.

The transition should therefore be seen as a bridge into continuing treatment rather than the finish line.

What is the U.S. regulatory status?

Oral naltrexone and extended-release injectable naltrexone have FDA-approved uses in opioid dependence/opioid use disorder treatment contexts after appropriate opioid abstinence. Long-acting naltrexone implants are not FDA-approved in the United States.

Patients in the United States should understand the distinction between evidence for naltrexone as a medication and evidence for a particular long-acting delivery system.

Medical review

Prepared for medical review — Review status: Pending.

Medical reviewer: Dr Fergus Law, BSc, MBChB, FRCPsych, Consultant Psychiatrist specialising in substance misuse and addiction.

This article provides general educational information and is not individual medical advice. Do not stop buprenorphine or start naltrexone without medical supervision. Precipitated withdrawal can be severe, and treatment choice should be individualized.

Selected evidence

• Randomized clinical trial of buprenorphine-to-extended-release naltrexone transition
• Seven-day outpatient buprenorphine-naltrexone transition study
• FDA prescribing information for extended-release naltrexone

Considering a medically managed transition? Request a confidential consultation with DeBinge.